Lupin receives FDA approval for generic Kapvay extended-release tablets

Lupin has received US FDA approval for generic Kapvay Extended-Release Tablets.

Lupin has received final approval for its Clonidine Hydrochloride extended-release tablets, 0.1 mg from the USFDA to market a generic version of Concordia Pharmaceuticals Inc’ Kapvay extended-release tablets, 0.1 mg.

At 15:10 hrs Lupin was quoting at Rs 997.10, down Rs 6.65, or 0.66 percent.

The share touched its 52-week high Rs 1,572.25 and 52-week low Rs 920.00 on 06 February, 2017 and 21 August, 2017, respectively.

Currently, it is trading 36.58 percent below its 52-week high and 8.38 percent above its 52-week low.

Market capitalisation stands at Rs 45,052.78 crore. Source : BSE